Molecular Partners AG
MP0632
solid cancers expressing MSLN and EpCAM
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for MP0632 in solid cancers expressing MSLN and EpCAM are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“Molecular Partners presented new pre-clinical data on its Switch-DARPin T cell engager, with MP0632 announced as lead, at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.”